葡萄糖胺激活肠道P-糖蛋白,抑制药物吸收
Qinghua Wu1, Qing Wang2, Xiaohong Luo3
1College of Pharmaceutical Sciences, Southwest University, Chongqing, 400715, China.
Nature communications
|July 2, 2025
概括
葡萄糖胺 (GlcN) 快速激活P-glycoprotein (P-gp) 药物流量,而不会改变表达,为急性中毒提供快速解药. 这种P-gp激活有助于排出毒素并维持细胞平衡.
科学领域:
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
- 毒理学 毒理学 毒理学
背景情况:
- P-glycoprotein (P-gp) 是胃肠道中一个关键的排泄物载体,限制药物吸收和去除异生菌.
- 现有的P-gp增强剂在几天内增加转运体表达,错过了急性中毒治疗的窗口.
- 需要快速起作用的P-gp调节器,以便立即排毒.
研究的目的:
- 为了确定P-glycoprotein (P-gp) 的快速起作用激活剂,用于急性中毒治疗.
- 研究由葡萄糖胺 (GlcN) 激活P-gp的机制.
- 为了探索GlcN作为抗毒中毒的解药的潜力.
主要方法:
- 研究了葡萄糖胺 (GlcN) 对P-gp介导的药物流量的影响.
- 评估了GlcN的聚合度对P-gp激活的影响.
- 研究了GlcN和P-gp之间的结合相互作用.
- 评估了GlcN在Paraquat中毒模型中的有效性.
主要成果:
- 葡萄糖胺 (GlcN) 快速增强P-gp流量活动,而不会改变P-gp表达水平.
- GlcN直接与P-gp结合,从而提高其运输效率.
- 通过GlcN激活P-gp取决于其聚合度 (需要<5度).
- 通过促进快速排毒,GlcN显示出作为帕拉克瓦特中毒的解毒剂的潜力.
结论:
- 葡萄糖胺 (GlcN) 是一种强效,快速起作用的P-gp激活剂,具有治疗急性中毒的治疗潜力.
- GlcN的机制涉及直接绑定和提高P-gp运输效率.
- 这一发现提供了一种新的解毒策略,并有可能开发新的代谢调节器.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
272
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
272
Drug Absorption: Factors Affecting GI Absorption
4.8K
The process of oral drug absorption can be influenced by several factors. Weakly acidic drugs tend to be absorbed more readily from the stomach due to their nonionized state. However, absorption may be less efficient in the upper intestine, where drugs are often ionized. Interestingly, despite the stomach's apparent advantage for drug absorption, its mucous layer can hinder diffusion. Its surface area is also smaller than the intestine's, which can further slow down the absorption rate.
4.8K
Factors Influencing Drug Absorption: Disease States and Pharmacology
830
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
830
Carrier-Mediated Transport
554
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
554
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
269
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
269
Dipeptidyl Peptidase 4 Inhibitors
270
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
270


